Alzheimer’s disease, a devastating neurodegenerative condition, affects an estimated 7.2 million Americans age 65 and older, according to the Alzheimer’s Association. Early and accurate diagnosis remains a significant challenge, but a new study offers a potential breakthrough. Researchers at Scripps Research have developed a novel blood test that focuses on the structure of proteins, rather than their quantity, to identify signs of Alzheimer’s disease and even mild cognitive impairment (MCI) with promising accuracy.
Current diagnostic methods often rely on measuring levels of amyloid beta (Aβ) and phosphorylated tau (p-tau) in blood or spinal fluid. While valuable, these biomarkers may not capture the earliest biological changes associated with the disease. This new approach, published in Nature Aging on February 27, 2026, could allow for earlier intervention and potentially more effective treatment strategies.
The Scripps Research team’s innovative test analyzes how proteins are folded in the bloodstream. “Many neurodegenerative diseases are driven by changes in protein structure,” explains senior author John Yates, a professor at Scripps Research. “The question was, are there structural changes in specific proteins that might be useful as predictive markers?” This research suggests the answer may be yes, opening a new avenue for Alzheimer’s detection.
Protein Misfolding and the Role of Proteostasis
For years, Alzheimer’s disease has been linked to the accumulation of amyloid plaques and tau tangles in the brain. Yet, scientists are increasingly recognizing that a broader failure in “proteostasis” – the system responsible for ensuring proteins are correctly folded and damaged proteins are removed – may be a key driver of the disease. As we age, this system becomes less efficient, increasing the likelihood of proteins misfolding. The Scripps Research team hypothesized that disruptions in brain proteostasis might be reflected in structural changes in proteins circulating in the blood.
How the New Blood Test Works
The researchers examined plasma samples from 520 participants, categorized into three groups: cognitively normal adults, individuals with mild cognitive impairment, and patients diagnosed with Alzheimer’s disease. Using mass spectrometry, they analyzed the structure of proteins, specifically looking at how exposed or buried certain locations within the proteins were – indicators of structural changes. Machine learning techniques were then applied to identify patterns associated with disease stage.
The results revealed a clear pattern: as Alzheimer’s progressed, blood proteins became less structurally “open.” These structural changes proved to be more informative than simply measuring protein concentrations. The test accurately classified participants as cognitively normal, with MCI, or with Alzheimer’s disease with approximately 83% overall accuracy. When comparing two groups directly – for example, healthy individuals versus those with MCI – accuracy rose to over 93%.
Three Key Proteins Identified
Among the proteins analyzed, three showed the strongest correlation with Alzheimer’s status: C1QA, involved in immune signaling; clusterin, which plays a role in protein folding and amyloid removal; and apolipoprotein B, a protein that transports fats in the bloodstream and contributes to blood vessel health. “The correlation was amazing,” says co-author Casimir Bamberger, a senior scientist at Scripps Research. “It was incredibly surprising to find three lysine sites on three different proteins that correlate so highly with disease state.”
The three-protein model proved reliable even when tested on independent participant groups and with blood samples collected months apart. Repeat tests taken months apart identified disease status with about 86% accuracy and reflected changes in diagnosis over time. The structural score also correlated with cognitive test results and, to a lesser extent, with MRI measurements of brain shrinkage.
Looking Ahead: Potential for Early Intervention
These findings suggest that analyzing protein structure in blood could complement existing amyloid and tau tests, offering a more comprehensive approach to Alzheimer’s diagnosis. “Detecting markers of Alzheimer’s early is absolutely critical to developing effective therapeutics,” Yates emphasizes. “If treatment can start before significant damage has been done, it may be possible to better preserve long-term memory.”
While promising, this blood test requires further validation through larger studies with longer follow-up periods before it can be implemented in clinical settings. Researchers are also investigating whether this structural profiling method could be applied to other neurodegenerative diseases, such as Parkinson’s disease, and even cancer.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the potential of this new blood test? Share your comments below, and please share this article with anyone who might find it helpful.
